Biofrontera AG announced that the Australian Patent Office (IP Australia) has granted the patent "Photodynamic therapy comprising two light exposures at different wavelengths" (AU 2018/437303B2) after the opposition period expired without a "notice of opposition" being received by the Office. The patent, filed by Biofrontera Bioscience GmbH, protects a number of innovations related to new illumination protocols for the treatment of skin diseases with photodynamic therapy (PDT). It covers a treatment protocol that combines the lower pain of daylight PDT with the higher cure rates and lower recurrence rates of conventional therapy.

The treatment method uses a photosensitizer in combination with two light exposures of different wavelengths and exposure durations. The application of a photosensitizer is followed first by a longer exposure to a broadband light (e.g., sunlight or light from an appropriate artificial light source) or blue light, followed by a subsequent, much shorter exposure to narrowband red light (e.g., light from Biofrontera's RhodoLED lamps). In the claims of this patent, this innovative illumination approach is linked to the performance of PDT with a drug containing a photosensitizer or its precursor.

In this respect, the use of the illumination combination protected in this patent also protects Biofrontera's drug Ameluz.